Drugmakers Seek Emergency Authorization For New COVID Vaccine

The video discusses the efficacy of a new COVID-19 vaccine by Sanofi and GlaxoSmithKline, which uses a recombinant protein technology. It compares this vaccine to those by Pfizer, Moderna, and Johnson & Johnson, highlighting differences in technology and efficacy rates. The Sanofi-GSK vaccine shows varying effectiveness against different severities of COVID-19. Booster doses significantly increase antibody levels, with notable results from mixing and matching vaccines. The video emphasizes the evolving nature of the virus and the importance of continued research and adaptation.

What is the basis of the Sanofi and GlaxoSmithKline vaccine technology?

• Recombinant protein technology

• Viral vector technology

• mRNA technology

• Inactivated virus technology

How does the recombinant protein vaccine by Sanofi GSK work?

• It uses a deactivated virus to trigger an immune response.

• It uses live attenuated virus to build immunity.

• It uses genetic code to teach cells to make proteins.

• It combines DNA segments to stimulate the immune system.

Which technology does the Pfizer and Moderna vaccines use?

• Inactivated virus technology

• mRNA technology

• Viral vector technology

• Recombinant protein technology

What was the effectiveness of the Sanofi GSK vaccine against severe disease?

• 84%

• 58%

• 75%

• 100%

What was the antibody level increase after the Sanofi GSK booster dose?

• 18 to 30 fold

• 84 to 153 fold

• 50 to 100 fold

• 10 to 20 fold